Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
Sivendran S, Liu Z, Portas L, Yu M, Hahn N, Sonpavde, Oh W, Galsky M. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treatment Reviews 2012, 38: 919-925. PMID: 22651902, DOI: 10.1016/j.ctrv.2012.05.001.Peer-Reviewed Original ResearchConceptsRisk of fatal adverse eventsFatal adverse eventsAdvanced solid tumorsVEGFR-TKIsSolid tumorsVascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyIncreased risk of FAEsVascular endothelial growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsSubgroup analysisReceptor-tyrosine kinase inhibitor therapyTyrosine kinase inhibitor therapyTreatment of solid tumor malignanciesReceptor tyrosine kinase inhibitorsVEGFR-TKI treatmentKinase inhibitor therapyTreatment-related mortalityTyrosine kinase inhibitorsSolid tumor malignanciesMeta-analysisRenal cell carcinomaExploratory subgroup analysisRandom-effects modelRandomized Controlled TrialsTKI treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply